Secondary outcomes
bleeding, death, ischemic stroke, petechiae, septic shock, epistaxis, embolism, heart failure
CEREBRAL HEMORRHAGE, BLEEDING, MYOCARDIAL INFARCTION, BOWEL PERFORATION, TRANSIENT ISCHEMIC ATTACK, THROMBOTIC OCCLUSION, ISCHEMIC STROKE, EMBOLISM, PETECHIAE, SECONDARY, ADVERSE EVENT, ACUTE CORONARY SYNDROME, SEPTIC SHOCK, EPISTAXIS, EVENTS, HEART FAILURE
The occurrence of secondary outcome events of target lesion revascularization, major amputation, serious adverse event, major bleeding, mortality were overall rare, with no difference between the two groups (Table Primary and secondary outcome events. Data were compared using Chi-square test or Fisher's exact test. *1 cerebral hemorrhage, 1 hemoglobin drop needing transfusion in the clopidogrel group. †2 epistaxis, 1 upperarm petechiae in the clopidogrel group, 1 vitreous hemorrahge in the sarpogrelate group. ‡Causes of death were septic shock (n = 1), heart failure (n = 1), unknown (n = 1) in clopidogrel group, and myocardial infarction (n = 1), bowel perforation (n = 1) in the sarpogrelate group. § Any serious adverse event defined as all-cause death, ischemic stroke, transient ischemic attack, systemic embolism, acute coronary syndrome, early thrombotic occlusion, major bleeding, and major amputation.Kaplan–Meier analysis of the (